Deerfield Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Deerfield Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-870,000	Closed	-$9.98M	–	233
2023 Q3	$9.98M	Hold	870,000	–	–	0.22%	57
2023 Q2	$22M	Buy	+870,000	New	+$27.1M	0.47%	45
2020 Q1	–	Sell	-900,000	Closed	-$14.6M	–	100
2019 Q4	$14.6M	Buy	+900,000	New	+$14M	0.47%	56
2018 Q1	–	Sell	-1,000,000	Closed	-$35.8M	–	126
2017 Q4	$35.8M	Buy	+1,000,000	New	+$28.7M	1.41%	25
2014 Q3	–	Sell	-256,500	Closed	-$8.72M	–	146
2014 Q2	$8.72M	Buy	256,500 +139,811	+120%	+$4.38M	0.35%	70
2014 Q1	$3.68M	Buy	+116,689	New	+$3.65M	0.15%	98

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Deerfield Management's RVNC Position: Q4 2023 in Review

Deerfield Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 870,000 shares — an estimated $9.98M sold.

Deerfield Management first reported a position in RVNC in Q1 2014 and held it in 6 quarters. The position peaked at $35.8M in Q4 2017. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

Deerfield Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
Deerfield Management sold 870,000 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $9.98M.
Deerfield Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 6 quarters.
Deerfield Management's Revance Therapeutics, Inc. position peaked at $35.8M in Q4 2017.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.